Virus inactivator

Abstract

To provide a virus inactivator that exhibits a viral inactivation effect for envelope viruses and also exhibits a superior viral inactivation effect for non-envelope viruses.SOLUTION: A virus inactivator comprising a phytic acid and at least one of the following component (A) and component (B). Component (A): at least one alkanediol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, and 1,2-decanediol. Component (B): at least one oily component selected from the group consisting of lavender oil, camphor leaf oil, rosemary oil, peppermint oil, copaiba oil, squalane, and liquid paraffin.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a virus inactivating agent. [Background technology]

[0002] Viruses are simple microorganisms with a protein outer shell that contains genes (DNA, RNA). Unlike bacteria, viruses cannot synthesize their own proteins. In order to reproduce, viruses must reach their preferred, or susceptible, cell (host cell) and, based on their DNA or RNA blueprint, use the cell's protein synthesis ability to mass-produce progeny. As a result, the cell is unable to produce its own proteins and dies. Viruses multiply by repeating the process of cell adsorption, invasion, uncoating, gene expression, gene translation, protein synthesis, virus particle formation, and release from the cell. These viruses include enveloped viruses, which have a lipid membrane called an envelope around their outer shell, and non-enveloped viruses, which lack this envelope.

[0003] Enveloped viruses can be effectively inactivated with alcohols and surfactants, which act on the envelope. Non-enveloped viruses, on the other hand, have a strong protein outer shell and are difficult to inactivate with common disinfectants such as alcohol and surfactants.

[0004] Examples of agents that have been shown to have an inactivating effect on non-enveloped viruses include chlorine-based disinfectants such as sodium hypochlorite. However, chlorine-based disinfectants have problems such as metal corrosion, skin irritation, and bleaching effects on clothing, which limits their use. For this reason, there has been a demand for a virus inactivating agent that is safe for use on the human body and has an inactivating effect on non-enveloped viruses.

[0005] Patent Document 1 describes a virus inactivating agent that can inactivate norovirus, which contains ethanol, carbonate, and an acid agent containing phytic acid. Patent Document 2 describes a virus inactivating agent that contains a specific essential oil. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Japanese Patent Application Publication No. 2019-182761 [Patent Document 2] International Publication No. 2020 / 017619 Summary of the Invention [Problem to be solved by the invention]

[0007] However, these virus inactivating agents cannot be said to be highly effective in inactivating non-enveloped viruses.

[0008] Therefore, an object of the present invention is to provide a virus inactivating agent that has not only an effect of inactivating enveloped viruses but also an excellent effect of inactivating non-enveloped viruses. [Means for solving the problem]

[0009] In view of the above circumstances, the present inventors have intensively investigated means for enhancing the inactivation effect of phytic acid on non-enveloped viruses, and have found that when phytic acid is used in combination with a 1,2-alkanediol or a specific oily component, which are ineffective when used alone, an excellent inactivation effect on non-enveloped viruses is achieved, leading to the completion of the present invention.

[0010] That is, the present invention provides a virus inactivating agent containing phytic acid and the following component (A) and / or component (B): Component (A): At least one alkanediol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, and 1,2-decanediol Component (B): at least one oily component selected from the group consisting of lavender oil, camphor leaf oil, rosemary oil, peppermint oil, copaiba oil, squalane, and liquid paraffin

[0011] The virus inactivating agent preferably contains component (A) and component (B).

[0012] The virus inactivating agent preferably contains 1.0 to 10.0 mass % of phytic acid, 0.01 to 10.0 mass % of component (A), and 0.01 to 10.0 mass % of component (B). [Effects of the Invention]

[0013] The virus inactivating agent of the present invention has an excellent virus inactivating effect not only on enveloped viruses but also on non-enveloped viruses. DETAILED DESCRIPTION OF THE INVENTION

[0014] The virus inactivating agent according to this embodiment is characterized by containing phytic acid and the following component (A) and / or component (B): Component (A): At least one alkanediol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, and 1,2-decanediol Component (B): at least one oily component selected from the group consisting of lavender oil, camphor leaf oil, rosemary oil, peppermint oil, copaiba oil, squalane, and liquid paraffin

[0015] Phytic acid The virus inactivating agent of this embodiment contains phytic acid, which is a substance also known as myo-inositol hexaphosphate (inositol hexaphosphate).

[0016] The content of phytic acid in the virus inactivating agent is not particularly limited, but is, for example, preferably 1.0 to 10% by mass, more preferably 1.5 to 8.0% by mass, and even more preferably 2.0 to 6.0% by mass. When the phytic acid content is 1.0% by mass or more, the virus inactivating effect against non-enveloped viruses tends to be more excellent. Furthermore, when the phytic acid content is 10% by mass or less, the feeling of use (reduced stickiness) tends to be excellent.

[0017] Ingredient (A) The virus inactivating agent of the present embodiment may contain, as component (A), at least one alkanediol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, and 1,2-decanediol. Among these, 1,2-pentanediol, 1,2-heptanediol, or 1,2-hexanediol is preferred as component (A) because they are particularly effective in inactivating non-enveloped viruses.

[0018] The content of component (A) in the virus inactivating agent is not particularly limited, but is, for example, preferably 0.01 to 10% by mass, more preferably 0.05 to 8.0% by mass, and even more preferably 0.1 to 6.0% by mass. When the content of component (A) is 0.01% by mass or more, the virus inactivating effect against non-enveloped viruses tends to be more excellent. Furthermore, from the viewpoint of low irritation, it is preferably 10% by mass or less.

[0019] The mass ratio of phytic acid to component (A) (phytic acid / component (A)) contained in the virus inactivating agent is not particularly limited, but is, for example, preferably 0.1 or more, more preferably 0.3 or more, and even more preferably 0.5 or more. Also, for example, it is preferably 300 or less, more preferably 150 or less, even more preferably 100 or less, and particularly preferably 80 or less. When the mass ratio of component (A) to phytic acid is within the above range, the virus inactivating effect against non-enveloped viruses tends to be more excellent.

[0020] ·Component (B) The virus inactivating agent of this embodiment may contain, as component (B), at least one oily component selected from the group consisting of lavender oil, camphor leaf oil, rosemary oil, peppermint oil, copaiba oil, squalane, and liquid paraffin. Among these, lavender oil is preferred as component (B) from the viewpoint that it has a particularly excellent virus inactivating effect on non-enveloped viruses.

[0021] The content of component (B) in the virus inactivating agent is not particularly limited, but is, for example, preferably 0.01 to 10.0% by mass, more preferably 0.1 to 5.0% by mass, and even more preferably 0.5 to 2.0% by mass. When the content of component (B) is 0.01% by mass or more, the virus inactivating effect against non-enveloped viruses tends to be more excellent. Furthermore, when the content is 10.0% by mass or less, the feeling of use (suppression of stickiness) tends to be excellent.

[0022] The mass ratio of phytic acid to component (B) (phytic acid / component (B)) contained in the virus inactivating agent is not particularly limited, but is, for example, preferably 0.01 or more, more preferably 0.1 or more, even more preferably 0.5 or more, and particularly preferably 1.0 or more. Also, for example, it is preferably 100 or less, more preferably 50 or less, even more preferably 20 or less, and particularly preferably 10 or less. When the mass ratio of component (B) to phytic acid is within the above range, the virus inactivating effect against non-enveloped viruses tends to be more excellent.

[0023] The virus inactivating agent according to this embodiment may contain water or a non-aqueous solvent (hereinafter, sometimes referred to as component (C)) as a component other than components (A) and (B).

[0024] Examples of water include pure water and ultrapure water such as ion-exchanged water, ultrafiltered water, reverse osmosis water, and distilled water.

[0025] Examples of non-aqueous solvents include monohydric alcohols having 2 to 4 carbon atoms, such as ethanol and isopropanol; polyhydric alcohols having 2 to 12 carbon atoms, such as ethylene glycol, propylene glycol, glycerin, and sorbitol (excluding component (A)); esters such as monoethyl or monobutyl ethers of ethylene glycol or propylene glycol, and monoethyl or monobutyl ethers of diethylene glycol or dipropylene glycol; aromatic compounds such as benzyl alcohol, benzyloxyethanol, ethylene oxide or propylene oxide adducts of phenolic compounds, and aromatic sulfonates such as p-toluenesulfonate and m-xylenesulfonate; liquefied petroleum gas (LPG) such as propane, propylene, n-butane, and isobutane; liquefied gases such as liquefied carbon dioxide and liquefied nitrogen; compressed gases such as nitrogen, carbon dioxide, air, and nitrous oxide; isopentane, n-pentane, dimethyl ether (DME), and fluorohydrocarbons. These non-aqueous solvents may be used alone or in combination.

[0026] The content of component (C) in the virus inactivating agent is not particularly limited, but can be, for example, the remainder excluding components (A), (B), and other components described below. The content of component (C) in the virus inactivating agent is not particularly limited, but is, for example, preferably 60% by mass or more, more preferably 70% by mass or more, even more preferably 80% by mass or more, and particularly preferably 90% by mass or more. From the viewpoint of improving the feel when used, the content is, for example, preferably 99.9% by mass or less, and more preferably 99.0% by mass or less.

[0027] The virus inactivating agent according to this embodiment may further contain components other than component (A), component (B), and component (C) (hereinafter referred to as "other components"). The other components are not particularly limited as long as they do not inhibit the effects of the present invention, and examples thereof include pH adjusters, buffers, surfactants, antioxidants, thickeners, dispersants, solubilizers, emulsifiers, stabilizers, excipients, binders, disintegrants, lubricants, chelating agents, preservatives, refreshing agents, moisturizers, colorants, fragrances, light stabilizers, and antifoaming agents.

[0028] When the virus inactivating agent contains an additive, the content of the additive can be adjusted appropriately within a range that does not impair the effects of the present invention.

[0029] The dosage form of the virus inactivating agent is not particularly limited and can be appropriately selected depending on the purpose of use. Examples include liquid formulations such as emulsions, suspensions, dispersions, and aerosols.

[0030] The method of using the virus inactivating agent is not particularly limited, and it can be used by a known method depending on the dosage form, and examples include an embodiment in which the virus inactivating agent is attached or sprayed onto the skin or hair (animal hair) of animals including humans, the surface of an article, or into air. These embodiments can inactivate viruses present on the skin or hair of humans or animals, the surface of an article, and in air.

[0031] The method for attaching the virus inactivating agent to the target is not particularly limited, and examples thereof include, when the virus inactivating agent is in the form of a liquid, a method of spraying or applying the virus inactivating agent to the target, a method of immersing the target in the virus inactivating agent, etc. After the virus inactivating agent is applied to the target, volatile components such as the aqueous solvent may volatilize.

[0032] The viruses targeted by the virus inactivating agent (target viruses) are not particularly limited. The virus inactivating agent can inactivate, for example, known enveloped viruses (viruses with an envelope) and non-enveloped viruses (viruses without an envelope). Among these, the virus inactivating agent is characterized by having an excellent virus inactivation effect, particularly against non-enveloped viruses.

[0033] Examples of enveloped viruses include influenza viruses (e.g., types A and B), coronaviruses, rubella viruses, Ebola viruses, measles viruses, varicella-zoster viruses, herpes viruses, respiratory syncytial viruses, SARS viruses, hepatitis viruses (e.g., types A to E), yellow fever viruses, and AIDS viruses. Examples of non-enveloped viruses include noroviruses, adenoviruses, rotaviruses, polioviruses, enteroviruses, coxsackieviruses, human parvoviruses, encephalomyocarditis viruses, and rhinoviruses.

[0034] The virus inactivating agent of the present invention exhibits an excellent virus inactivating effect not only on enveloped viruses but also on non-enveloped viruses.

[0035] Examples of objects to be treated or processed with the virus inactivating agent include the surface of the skin, such as fingers, and body hair if the object is a human (particularly the human body), the skin and animal hair if the object is an animal, walls, floors, furniture, clothing, medical instruments, electronic devices, industrial products, and various outdoor and indoor installations (e.g., street trees and monuments) if the object is an article, and indoor spaces, outdoor spaces, etc. The virus inactivating agent of the present invention can be used as an antibacterial agent in various fields, such as medical, industrial, cleaning, food, and household use, or can be combined with other drugs to prepare an antibacterial agent.

[0036] The method for producing the virus inactivating agent is not particularly limited. For example, the virus inactivating agent can be prepared by blending and mixing phytic acid, component (A) and / or component (B), and optionally component (C) in predetermined proportions. [Example]

[0037] The present invention will be described in more detail below based on examples, but the present invention is not limited to these examples.

[0038] [Examples and Comparative Examples] Preparation of test compositions Test samples of Examples 1 to 13 and Comparative Examples 1 to 15 were obtained according to the formulations shown in Tables 1 and 2. The numerical values ​​of the components in the tables are in units of mass (g). The virus inactivation test used virus solutions of a non-enveloped virus (Coxsackievirus A group 7 (CA7)) and an enveloped virus (herpes simplex virus type 2). Specifically, two mixtures were prepared by mixing 100 μL of the virus solution with 900 μL of the test sample. A 0.1 N sodium thiosulfate-containing medium was added to one mixture immediately after mixing (sample A) and to the other mixture 60 seconds later (sample B), to prepare post-treatment mixtures. Sensitive cells (Vero cells) were sensitized with 10 μL of each post-treatment mixture, and then 0.1 mL of maintenance medium was added and the cells were cultured for 3–5 days. The infectivity titers for sample A and sample B were determined by observing the cytopathic effect. The infectivity titers were calculated as the 50% cytopathic endpoint (TCID ) statistically calculated using the Karber formula. 50 The difference between the logarithmic value of the infectivity titer of sample A and the logarithmic value of the infectivity titer of sample B (logarithmic value of the infectivity titer of sample A - logarithmic value of the infectivity titer of sample B) was used as the antiviral activity value (Log TCID 50 The antiviral activity value was determined as follows: The higher the antiviral activity value, the greater the virus inactivation effect. The virus inactivation effect was evaluated according to the following criteria. The results are shown in Tables 1 and 2.

[0039] (Evaluation criteria) "AA": Antiviral activity value is 4 logs or more "A": Antiviral activity value is 3 logs or more and less than 4 logs "B": Antiviral activity value is 2 logs or more and less than 3 logs "C": Antiviral activity value is less than 2 logs

[0040] [Table 1]

[0041] [Table 2]

Claims

1. A virus inactivating agent comprising phytic acid and the following component (A) and / or component (B): Component (A): At least one alkanediol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, and 1,2-decanediol Component (B): At least one oily component selected from the group consisting of lavender oil, camphor leaf oil, rosemary oil, peppermint oil, copaiba oil, squalane, and liquid paraffin.

2. The virus inactivating agent according to claim 1, comprising the component (A) and the component (B).

3. 1.0 to 10.0% by mass of phytic acid, 0.01 to 10.0 mass% of component (A), 3. The virus inactivating agent according to claim 2, containing 0.01 to 10.0 mass % of component (B).

Images